Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
Colorcon
McKinsey
Julphar
Accenture

Generated: September 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMLODIPINE AND OLMESARTAN MEDOXOMIL

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Clinical Trials for Amlodipine And Olmesartan Medoxomil

Trial ID Title Status Sponsor Phase Summary
NCT00185133 Study of co-Administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension Completed Daiichi Sankyo Inc. Phase 3 This study assesses the efficacy and safety of co-administration of olmesartan medoxomil plus amlodipine in mild to severe hypertensive patients older than 18 years of age
NCT00220220 Amlodipine as Add-on to Olmesartan in Hypertension Completed Sankyo Pharma Gmbh Phase 3 Test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with olmesartan alone.
NCT00220233 Olmesartan as an Add-on to Amlodipine in Hypertension Completed Sankyo Pharma Gmbh Phase 3 This study is to test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with amlodipine alone
NCT00311155 Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension Completed Sankyo Pharma Gmbh Phase 4 This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension.
NCT00649389 Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension Completed Daiichi Sankyo Inc. Phase 3 To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
NCT00654745 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics Completed Daiichi Sankyo Inc. Phase 4 To determine if olmesartan plus amlodipine combination therapy alone and with hydrochlorothiazide will be safe and effective to reduce high blood pressure in hypertensive, type 2 diabetic subjects.
>Trial ID >Title >Status >Phase >Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Amlodipine And Olmesartan Medoxomil

Condition Name

Condition Name for Amlodipine And Olmesartan Medoxomil
Intervention Trials
Hypertension 6
Essential Hypertension 6
Healthy Subjects 2
Type 2 Diabetes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Amlodipine And Olmesartan Medoxomil
Intervention Trials
Hypertension 10
Syndrome 1
Metabolic Syndrome X 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Amlodipine And Olmesartan Medoxomil

Trials by Country

Trials by Country for Amlodipine And Olmesartan Medoxomil
Location Trials
United States 122
Germany 5
Philippines 3
Belgium 2
Netherlands 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Amlodipine And Olmesartan Medoxomil
Location Trials
South Carolina 4
Virginia 4
Oklahoma 4
Tennessee 4
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Amlodipine And Olmesartan Medoxomil

Clinical Trial Phase

Clinical Trial Phase for Amlodipine And Olmesartan Medoxomil
Clinical Trial Phase Trials
Phase 4 5
Phase 3 7
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Amlodipine And Olmesartan Medoxomil
Clinical Trial Phase Trials
Completed 13
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Amlodipine And Olmesartan Medoxomil

Sponsor Name

Sponsor Name for Amlodipine And Olmesartan Medoxomil
Sponsor Trials
Daiichi Sankyo Inc. 6
Sankyo Pharma Gmbh 3
Torrent Pharmaceuticals Limited 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Amlodipine And Olmesartan Medoxomil
Sponsor Trials
Industry 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Healthtrust
Harvard Business School
Express Scripts
Merck
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.